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Dear Editor,
Intravesical administration of Bacille Calmette-Guérin (BCG),
with live attenuated strain of Mycobacterium bovis, is the main-
stay therapy of superficial bladder cancer. BCG disease is
uncommon in immunocompetent adults, accounting for less
than 5% of patients1 who underwent intravesical adminis-
tration of BCG for superficial bladder cancer. It may present
with a wide spectrum of clinical presentation, severity and
variability of onset after the first intravesical administration
of BCG immunotherapy. Therefore, it poses a diagnosis chal-
lenge for clinicians. We report two cases of disseminated BCG,
a rare complication of intravesical BCG administration, which
presented with distinct features regarding time between the
first intravesical administration and onset of presentation and
clinical manifestations.
Case 1
A 66-year old man, with a past history of Pott disease in
his childhood, underwent intravesical administration of BCG
for eight weeks. One week after the last treatment he pre-
sented with fever and urinary symptoms. Although antibiotic
was initiated, the patient progressed with clinical worsening
and onset of respiratory symptoms. A thoracic CT revealed
ground-glass opacification throughout both lungs. Due to his
past history of tuberculosis and imagiologic features he was
admitted to the hospital for further investigation. The latter
wasunremarkable including both bronchial aspirate andurine
mycobacterial culture which returned negative. Since there
was a close temporal relationship between the BCG instilla-
tion and the development of symptoms and no other cause
was identified, a systemic BCG disease with pneumonitis was
assumed and 6-month triple therapy was initiated. However,
and due to persistent fever despite treatment, corticosteroids
were introduced with posterior apyrexia and clinical and
radiological improvement.s
Case 2
A 63-year-old man, presented with fever with no apparent
focus and elevated hepatic enzymes only one day after the
first intravesical treatment with BCG. The patient was started
on empiric antibiotics with no clinical or laboratory improve-
ment. Tumor markers, serum antibodies and serology were
unremarkable and microbiologic exams returned negative.
Since the patient evolved with pancytopenia a myelogram
was performed that revealed phagocytosis phenomena. In
the absence of response to antibiotics and since no other
cause was identified for the presented features, dissemi-
nated BCG infection with hemaphagocytic syndrome was
assumed and triple therapy was administered. Soon after,
hepatic enzymes elevated and anon-hepatotoxic regimenwas
temporarily made. After full laboratory recovery, triple ther-
apy was introduced without new toxicity and with clinical
improvement.
Complications associated with BCG intravesical instilla-
tion are very uncommon and highly variable, ranging from
prostatitis to pneumonitis and sepsis. They are classified as
local disease, if manifestations are limited to genitourinary
tract, or systemic if disseminated BCGdisease, persistent fever
with bone marrow, hepatic or pulmonary involvement are
demonstrated.1
Gonzalez et al. stratified BCG disease spectrum into early
and late-presentation disease if manifestations appear within
three months after the first instillation or one year after the
first BCG treatment, respectively.2 There is a significant over-
lap between the two classifications since early-presentation
disease is generally characterized by systemic manifestations
and late-presentation disease is almost exclusive of genitouri-
nary tract.
1Pathogenesis is not fully known but some authors con-
sider that BCG disease is not unequivocally caused by an
active infection, but also by some degree of hypersensitivity
reaction to Mycobacterium bovis. This is particularly important
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n early-presentation disease where hypersensitivity features
redominate and significant improvement occur when cor-
icosteroids are introduced.3 First-line treatment consist in
combination of rifampicin, isoniazid, and ethambutol4
lthough there is no consensus regarding its duration.1
Diagnostic criteria are not established but response to anti-
uberculosis treatment, with or without corticosteroids, and
he exclusion of other causes is considered the cornerstone for
CG disease diagnosis, since cultures often return negative.1
Although the patients generally display a good prognosis
ith a mortality rate around 5%, in patients with 65 years or
lder disseminated BCG disease or with vascular involvement
ave higher mortality.1
In conclusion, the reported cases are representative of
he highly variable spectrum of BCG disease manifestations
nd, although they occurred during BCG treatment which
llowed a prompt diagnosis and treatment, sometimes a high
ndex of suspicion based on history of previous exposure to
CG and clinical awareness is needed since complications
ave been diagnosed in up to 17 years after BCG intravesical
dministration.1
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